Strategic Acquisition Context Disarm Therapeutics was acquired by Lilly for up to 1.3B in 2020, indicating a strong interest from large pharma in axonal degeneration therapeutics and potential ongoing integration or collaboration dynamics that sales teams can leverage when approaching Lilly or its network for subsequent opportunities.

Neurology Focus Opportunity Disarm targets axonal degeneration across central, ocular, and peripheral nervous systems in diseases like MS, ALS, glaucoma, and neuropathies, presenting cross-disease selling opportunities to pharma and biotech partners seeking disease-modifying solutions in neurology.

SARM1 Inhibitor Portfolio The core asset class is SARM1 inhibitors aimed at preventing axonal loss, suggesting partnerships or licensing discussions around preclinical to clinical expansions, combination strategies, or platform collaborations to broaden the pipeline.

Small to Mid-Size Partner Fit With a modest headcount (11-50) and prior VC backing, Disarm may be open to collaboration, co-development, or out-licensing deals with mid-sized biotechs or larger pharma seeking to augment neurology portfolios without immediate large-scale integration.

Funding and Revenue Signals Current revenue and funding levels indicate early-stage commercialization potential; sales efforts can target investors, potential strategic buyers, or follow-on collaborations that align with Disarm’s milestones and development timelines.